These results preliminarily present an opportunity for improvement in the diagnosis and treatment of cervical cancer, by revealing S100A16 as a new target for cervical cancer therapy and uncovering its apparent role in cellular susceptibility to an array of current chemotherapeutic drugs. This evidence concerns the gene S100A16 and cervical carcinoma.